University of Halle Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Halle Germany (1691)

Organization Overview

First Clinical Trial
2002
NCT01222052
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Department of Internal Medicine IV, University Hospital Halle | Dpt. Gynecology University Halle Germany | Hospital BG-Kliniken Bergmannstrost, Halle | Klinikum Weissenfels | Krankenhaus Martha-Maria Halle-Doelau | University Hospital Halle, Germany | University Medical Center Halle, Department of Hematology and Oncology | University of Halle Medical Faculty | University of Halle-Wittenberg, Department of Sports

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Infertility (Phase 3)

Infertility, Male (Phase 3)

Intervertebral Disc Degeneration (Phase 2)

Intervertebral Disc Displacement (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms, Second Primary (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 16